The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
Daily Summary: A grim end to a difficult week
Without Jensen: Markets at the Mercy of the Fed
US OPEN: Selling pressure eases, Anthropic gives back post-IPO gains
Market Wrap: Global stocks post 7th consecutive session of losses, Anthropic failed to reassure the market (20.11.2026)